Hanmi Science Co., Ltd. (KRX: 008930)

Market Cap	1.89T
Revenue (ttm)	1.28T
Net Income (ttm)	104.96B
Shares Out	67.71M
EPS (ttm)	1,549.15
PE Ratio	18.04
Forward PE	n/a
Dividend	200.00 (0.72%)
Ex-Dividend Date	Jun 27, 2024

Volume	73,571
Average Volume	124,744
Open	28,050
Previous Close	27,950
Day's Range	27,900 - 28,500
52-Week Range	25,750 - 52,500
Beta	0.96
RSI	43.86
Earnings Date	Feb 6, 2025

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 444
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2023, Hanmi Science's revenue was 1.25 trillion, an increase of 19.30% compared to the previous year's 1.05 trillion. Earnings were 115.12 billion, an increase of 66.34%.